CanSino Biologics Inc. announced that the phase I/II clinical trial of the recombinant poliovirus vaccine developed by the company has recently been launched in Indonesia, and the first participant in phase I has been enrolled. This vaccine is a recombinant poliovirus vaccine based on virus-like particles, developed using the company's protein structure design and VLP assembly technology, and is a non-infectious poliovirus vaccine that does not rely on live viruses during production, with expected good safety and immunogenicity.
康希诺：重组脊髓灰质炎疫苗I/II期临床试验启动并完成首例入组
CanSino Biologics Inc.: The phase I/II clinical trial of the recombinant poliovirus vaccine has been launched and the first participant has been enrolled.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Investment Course
Choose stocks based on financial reports
Quickly master financial season learning guidelines
When the financial season comes, company stock prices are the most likely to rise and fall, and many excellent investors will see the financial season as a good
[2025.2] How should NVIDIA's performance be viewed? The key indicator to watch for short-term stock prices is this.
NVIDIA has been one of the best-performing Technology giants in the US stock market over the past two years, and since 2024, its stock price has experienced sig
How to view Tesla's performance in January 2025? Pay attention to these four key points.
It's earnings season for US stocks again. The performance of giant companies not only affects their own stock prices but also influences the overall trend of th